IP Library › Granted Patent US 10,206,894
Granted Patent B2
US 10,206,894 · App. 15/702,186 · Granted Feb 19, 2019

Compounds for use in treatment of mucositis

Inventors: Richard W. Scott (Radnor, PA); Bozena Korczak (Wayne, PA)
Assignee: Innovation Pharmaceuticals Inc.
A61K31/167A61K9/006A61K31/4025A61K31/4178A61K31/505A61K31/506A61K38/18A61K38/1825A61K45/06C07D239/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,206,894
App. No.
15/702,186
Granted
Feb 19, 2019
Kind
B2
Abstract

The present invention provides methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.

Claims (20)

1. An oral, buccal, or sublingual pharmaceutical composition comprising a compound of the formula

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the compound is present at 1 mg/ml, 3 mg/ml, or 10 mg/ml.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a liquid.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a rinse.

4. The pharmaceutical composition of claim 1 , wherein the compound is present at 1 mg/ml.

5. The pharmaceutical composition of claim 1 , wherein the compound is present at 3 mg/ml.

6. The pharmaceutical composition of claim 1 , wherein the compound is present at 10 mg/ml.

7. The pharmaceutical composition of claim 1 , further comprising an analgesic.

8. The pharmaceutical composition of claim 1 , further comprising an antibiotic.

9. The pharmaceutical composition of claim 1 , further comprising palifermin.

10. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is an oral pharmaceutical composition.

11. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a buccal pharmaceutical composition.

12. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a sublingual pharmaceutical composition.

13. An oral, buccal, or sublingual pharmaceutical composition comprising a compound of the formula

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and further comprising palifermin.

14. The pharmaceutical composition of claim 13 , wherein the pharmaceutical composition is a liquid.

15. The pharmaceutical composition of claim 13 , wherein the pharmaceutical composition is a rinse.

16. The pharmaceutical composition of claim 13 , wherein the compound is present at 1 mg/ml.

17. The pharmaceutical composition of claim 13 , wherein the compound is present at 3 mg/ml.

18. The pharmaceutical composition of claim 13 , wherein the compound is present at 10 mg/ml.

Assignments (3)
BANKRUPTCY COURT ORDER/ASSET PURCHASE AGREEMENT Recorded Nov 14, 2017
From: POLYMEDIX, INC.
To: CELLCEUTIX CORPORATION
Reel/Frame 044437/0314 →
CHANGE OF NAME Recorded Nov 14, 2017
From: CELLCEUTIX CORPORATION
To: INNOVATION PHARMACEUTICALS INC.
Reel/Frame 044751/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2017
From: SCOTT, RICHARD W.; KORCZAK, BOZENA
To: POLYMEDIX, INC.
Reel/Frame 044118/0588 →
Continuity (6)
Continuation 15239460 · Aug 17, 2016
Continuation 14836177 · Aug 26, 2015
Continuation 14456202 · Aug 11, 2014
Continuation 13471689 · May 15, 2012
Provisional Application 61486455 · May 16, 2011
Related Publication 20180064664A1 · Mar 8, 2018